Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To determine whether home monitoring with the ForeseeHome device (Notal Vision Ltd, Tel Aviv, Israel), using macular visual field testing with hyperacuity techniques and telemonitoring, results in earlier detection of age-related macular degeneration-associated choroidal neovascularization (CNV), reflected in better visual acuity, when compared with standard care. The main predictor of treatment outcome from anti-vascular endothelial growth factor (VEGF) agents is the visual acuity at the time of CNV treatment.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ophthalmology

Title: Ophthalmology

Publisher: Elsevier BV

ISSN (Electronic): 1549-4713

ISSN (Print): 0161-6420

Publication date (Electronic): Feb 2014

Volume: 121

Issue: 2

Affiliations

[1 ] Clinical Trials Branch, National Eye Institute/National Institutes of Health, Bethesda, Maryland. Electronic address: echew@nei.nih.gov.

[2 ] EMMES Corporation, Rockville, Maryland.

[3 ] The Retina Division, the Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.

[4 ] Elman Retina Group, PA, Baltimore, Maryland.

[5 ] University of Wisconsin-Madison, Madison, Wisconsin.

[6 ] Ophthalmic Consultants of Boston, Boston, Massachusetts.

[7 ] Medical College of Wisconsin-Milwaukee, Milwaukee, Wisconsin.

[8 ] Retina Group of Washington, Washington, DC.

Article

Publisher Item ID: S0161-6420(13)00952-4 Mid ID: NIHMS535453

DOI: 10.1016/j.ophtha.2013.10.027

PMC ID: 3918479

PubMed ID: 24211172

SO-VID: c0660254-9451-4041-932d-591a1bc7abfc

History

Data availability:

Comments

Comment on this article

scite_

Cited by 69

See all cited by

- Version 1